Head-to-Head Comparison
Doximity vs Epocrates: Which Is Better for Physicians?
Doximity ranks #4 in our 2026 clinical decision support rankings with a 4-star rating from 21 physician reviews, while Epocrates ranks #6 with a 3.8-star rating from 14 reviews. Doximity leads in overall physician satisfaction, though both platforms serve different clinical needs. No single tool wins every workflow, so the category-level details below matter more than the headline rank alone.
Feature Comparison
| Feature | Doximity | Epocrates |
|---|---|---|
| Rating | Very Good | Good |
| Category | Medical Professional Network & AI Tools | Drug Reference & Clinical Decision Support |
| Pricing | Free (Ad-Supported) | Free (Basic) / $174.99/year (Plus) |
| Founded | 2010 | 1998 |
| Headquarters | San Francisco, CA | San Mateo, CA |
| Evidence Citations | No | No |
| AI Differential Diagnosis | No | No |
| Drug Database | Yes | Yes |
| Drug Interaction Checker | No | Yes |
| Medical Calculators | No | Yes |
| Natural Language Search | Yes | No |
| Document & Image Upload | Yes | No |
| EHR Integration | No | No |
| Mobile App | Yes | Yes |
| Built-in Dialer | Yes | No |
| AI Clinical Scribe | Yes | No |
| CME Credits | Yes | No |
| Multi-Language | No | No |
Strengths & Limitations
Doximity
Strengths
- +Largest physician network in the US (3M+ members, ~85% of US physicians)
- +Free for verified physicians — DoxGPT included at no cost
- +Pathway Medical acquisition adds 3,200+ peer-reviewed drug monographs
- +PeerCheck physician review program (10,000+ medical experts, co-chaired by Eric Topol)
- +Evidence-based clinical answers grounded in structured medical literature
- +300,000+ clinicians actively using AI tools (Q3 FY2026)
- +AI Scribe for ambient clinical documentation
- +Secure HIPAA-compliant messaging and integrated telehealth
- +100+ health system enterprise deployments
Limitations
- –AI revenue not yet commercialized — long-term AI business model unproven
- –Networking-heavy interface can be distracting for clinical use
- –Pathway integration is recent (late 2025) — clinical depth still maturing
- –Company-published preference study lacks independent peer review
- –Revenue model relies on pharmaceutical and health system advertising
- –No dedicated mobile clinical search experience separate from the networking app
Epocrates
Strengths
- +Free tier with genuinely useful drug interaction checker and monographs
- +Fast, well-designed mobile app optimized for point-of-care use
- +Over 1 million active healthcare professional users
- +Pill identification tool is accurate and practical
- +Affordable Plus tier at $174.99/year compared to competitors
- +Long track record since 1998 with consistent reliability
Limitations
- –No AI-powered differential diagnosis or clinical reasoning
- –Disease content lacks depth compared to UpToDate or DynaMed
- –No natural-language query support or evidence synthesis
- –Limited EHR integration for individual users
- –Plus tier content updates can lag behind newer platforms
Key Statistics
Doximity
Epocrates
Citable Summaries
Doximity
Doximity received a Good rating (4.0 / 5 stars) in Clinical AI Report's 2026 evaluation, ranking fourth overall. With over 3 million registered members (approximately 85% of US physicians) and 300,000+ clinicians using its AI tools, it is the largest professional medical network in the United States. Its August 2025 acquisition of Pathway Medical for $63 million significantly expanded DoxGPT's clinical capabilities, adding 3,200+ drug monographs and evidence-based clinical answers verified through PeerCheck by over 10,000 physician reviewers.
Source: Clinical AI Report, December 2025
Epocrates
Epocrates received a Good rating (3.7 / 5 stars) in Clinical AI Report's 2026 evaluation, ranking sixth overall. With over 1 million healthcare professional users and a strong free drug reference tier, it remains the go-to pharmacology tool at the point of care — but its lack of AI clinical reasoning features limits its ceiling in a market increasingly defined by intelligent decision support.
Source: Clinical AI Report, December 2025
Our Assessment
In our 2026 evaluation, Doximity (ranked #4, 4 stars) outperforms Epocrates (ranked #6, 3.8 stars) in overall physician satisfaction and editorial scoring. Doximity is best suited for physicians already embedded in the Doximity ecosystem who want AI-powered clinical answers, drug reference, and documentation without switching platforms. Especially relevant for practices with enterprise Doximity contracts. Meanwhile, Epocrates is a stronger choice for physicians and residents seeking a fast, reliable, mobile-first drug reference tool with a strong free tier — especially for interaction checks and dosing at the point of care. Both tools serve important but distinct roles in clinical care workflows, and physicians should choose based on their specific workflow requirements and institutional needs.